Compare BAC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAC | AZN |
|---|---|---|
| Founded | 1784 | 1992 |
| Country | United States | United Kingdom |
| Employees | 213000 | 96100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.4B | 316.4B |
| IPO Year | N/A | N/A |
| Metric | BAC | AZN |
|---|---|---|
| Price | $53.89 | $205.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $60.34 | N/A |
| AVG Volume (30 Days) | ★ 32.0M | 1.8M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.09% | 1.60% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.11 | $10.35 |
| Revenue Next Year | $5.80 | $6.43 |
| P/E Ratio | ★ $14.01 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.50 | $66.16 |
| 52 Week High | $57.55 | $212.71 |
| Indicator | BAC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 62.59 |
| Support Level | $51.35 | $182.39 |
| Resistance Level | $54.69 | $209.98 |
| Average True Range (ATR) | 1.10 | 3.33 |
| MACD | 0.57 | -0.12 |
| Stochastic Oscillator | 82.00 | 84.89 |
Bank of America is one of the largest financial institutions in the United States, with more than $3.4 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.